Neurologic Drugs : Parkinsonism
OSTAL1 “Stalevo FC tablet”
Each tablet contains carbidopa monohydrate 25 mg, entacapone 200 mg, levodopa 100 mg.
適應症：表現藥效終期運動功能波動現象，以左多巴/多巴脫羧基脢抑制劑無法達到穩定治療效果之巴金森氏症病人。
Usual dose:
Transfer p’ts NOT currently treated with entacapone:
If current levodopa dose is > 600 mg/day, levodopa dose reduction likely required with addition of entacapone; p’ts should first be titrated individually with carbidopa/levodopa product and entacapone product, then transferred to corresponding dose of Stalevo once stabilized, max. 8 tab/day.
If current levodopa dose is≦600 mg/day and no dyskinesias, transferred to corresponding dose of Stalevo, max. 8 tab/day.
Transfer p’ts treated with carbidopa/levodopa and entacapone: p’ts currently taking 200 mg entacapone with each dose of standard carbidopa/levodopa can be directly switched to corresponding amounts of carbidopa and levodopa in Stalevo, max. 8 tab/day.
Contraindication:
Using non-selective MAOI within 2 wks, narrow angle glaucoma; history of melanoma or suspicious, undiagnosed skin lesions.
Precaution: biliary obstruction, endocrine disease, hepatic disease.
Adverse effect:
Common: abdominal pain, diarrhea, nausea, confusion, dizziness, somnolence, hallucinations, discolored urine, fatigue.
Serious: heart disease, orthostatic hypotension, diarrhea, dyskinesia, psychotic disorder.
健保使用規範：限用於表現藥效終期運動功能波動現象，以左多巴/多巴脫羧基脢抑制劑無法達到穩定治療效果之巴金森氏症病人。（95/9/1）